Clinical Trials Logo

Follicular Lymphoma clinical trials

View clinical trials related to Follicular Lymphoma.

Filter by:

NCT ID: NCT05990465 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Start date: April 2024
Phase: Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.

NCT ID: NCT05934838 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Start date: October 4, 2023
Phase: Phase 1
Study type: Interventional

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.

NCT ID: NCT05934097 Withdrawn - Clinical trials for Mantle Cell Lymphoma

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Start date: December 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.

NCT ID: NCT05929222 Recruiting - Follicular Lymphoma Clinical Trials

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

FIL_GAZEBO
Start date: December 14, 2023
Phase: Phase 3
Study type: Interventional

Prospective, multicenter, open label, phase III randomized clinical trial in previously untreated Follicular Lymphoma in early stage. Patients will be randomized to receive Radiotherapy or Radiotherapy plus Obinutuzumab.

NCT ID: NCT05923502 Not yet recruiting - Follicular Lymphoma Clinical Trials

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Start date: October 20, 2023
Phase:
Study type: Observational

This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.

NCT ID: NCT05899621 Recruiting - Follicular Lymphoma Clinical Trials

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Start date: June 1, 2023
Phase:
Study type: Observational

This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma

NCT ID: NCT05867030 Withdrawn - Follicular Lymphoma Clinical Trials

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Start date: July 28, 2023
Phase: Phase 1
Study type: Interventional

A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

NCT ID: NCT05846763 Recruiting - Follicular Lymphoma Clinical Trials

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Start date: November 1, 2022
Phase:
Study type: Observational

This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.

NCT ID: NCT05816850 Recruiting - Follicular Lymphoma Clinical Trials

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

FIL_FOLL-BIO
Start date: September 19, 2023
Phase:
Study type: Observational

This is a Multicenter, Retrospective, Biological study ancillary to FOLL12 trial to evaluate the role of EZH2 aberrations in patient with FL treated with immunochemotherapy. Moreover, several novel biomarkers of FL will be investigated.

NCT ID: NCT05805605 Recruiting - Clinical trials for Myelodysplastic Syndromes

Allo HSCT Using RIC and PTCy for Hematological Diseases

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.